Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
1998-11-20
2001-02-13
Navarro, Albert (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S137100, C424S141100, C424S144100, C424S154100, C530S388100, C530S388700, C530S388730, C530S388850
Reexamination Certificate
active
06187308
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to monoclonal antibodies specific for an epitope on the leukocyte adhesion receptor &bgr;-chain which can be used to suppress intercellular leukocyte adhesion.
DESCRIPTION OF THE BACKGROUND ART
Human immunodeficiency virus (HIV) is the etiologic agent of acquired immunodeficiency syndrome (AIDS), a fatal disease characterized by profound immunosuppression, opportunistic infections, and neuropathies. Although only a small fraction of circulating lymphocytes are infected with the virus, there is a marked loss of T cells bearing the virus receptor CD4. The depletion of CD4
+
-T cells appears to contribute significantly to the immunosuppression associated with AIDS. Syncytium formation resulting from HIV-induced cell fusion has been shown to be the primary cytopathic effect of the virus in vitro and has been postulated to account for the loss of CD4
+
-T cells in vivo. CD4 through its interaction with the HIV envelope glycoprotein gp120 plays an important role in syncytium formation.
Although the CD4 receptor appears to play a significant role in the etiology of AIDS, several observations suggest that molecules on the surface of uninfected cells other than CD4 are also involved in HIV-induced cell fusion. s First, fusion of HIV-infected cells to uninfected cells does not correlate with CD4-density on the surface of the uninfected cells. In addition, whereas transfection of non-lymphoid human cells with CD4 receptors renders such cells capable of fusion to HIV-infected cells, this is not true for CD4-transfected mouse cells. Finally, there is a disparity in the capacity of sera from AIDS patients to block binding of HIV particles to CD4
+
-cells and the capacity of the same sera to block fusion of HIV-infected cells to CD4
+
-uninfected cells.
CD4 interacts directly with class II major histocompatibility complex (MHC) molecules in class II MHC-restricted T helper cell responses. The involvement of the leukocyte adhesion receptor (LAR) LFA-1, in such responses has been demonstrated using anti-LFA-1 monoclonal antibodies (mAb). Structural similarities between gp120 and class II MHC suggested that the binding of gp120 to CD4 may mimic the interaction between class II MHC molecules and CD4. By analogy, the role of LAR in HIV-mediated cell fusion was examined. In the present invention, a mAb against LFA-1 completely inhibits HIV-mediated fusion of uninfected T cell blasts to HIV infected cells. This result indicates that LFA-1 is involved in HIV-induced syncytium formation, a major cytopathic mechanism of the virus.
The LFA-1 molecule, which is expressed on T and B lymphocytes as well as on macrophages, thymocytes, granulocytes, and a subpopulation of bone marrow cells, is composed of two non-covalently associated polypeptides of 175,000 Kd (&agr;; CD11a) and 95,000 Kd (&bgr;; CD18). The &bgr;-chain of LFA-1 is also common to two other leukocyte antigens: Mac-1 (&agr;-chain 165,000 Kd; CD11b); the type-three complement receptor; and LeuM5 (&agr;-chain 150,000 Kd; CD11c), a molecule possibly associated with type-four complement receptor activity. Although the three &agr;-subunits differ in size, there is evidence suggesting that all three subunits are encoded by a single gene or duplicated genes. cDNA encoding the human &bgr;-chain has been cloned and found to be 50% identical in primary structure to the &bgr;-chain of integrin, a chick fibroblast fibronectin receptor. These studies and others have shown that molecules of the LFA-1 glycoprotein family are members of the larger arginine-glycine-aspartate (RGD) adhesion family known as integrins.
At present, methods of limited effectiveness exist for the treatment of AIDS or other disorders in which the intercellular interaction of lymphocytes helps to mediate the pathologic state. Those drugs which are administered generally have severe contraindications associated with their use. Consequently, a considerable need exists for a therapeutic agent which can inhibit lymphocytic intercellular interaction in AIDS and other immune response mediated disorders.
SUMMARY OF THE INVENTION
One way to ameliorate immune response mediated disorders would be to suppress intercellular leukocyte adhesion using a monoclonal antibody which binds to a leukocyte adhesion receptor. In so doing, intercellular leukocyte binding is suppressed thereby decreasing the likelihood of cell-to-cell transmition of infectious agents and immune response activation.
In order to provide a means to ameliorate immune response mediated disorders, the inventor has developed monoclonal antibodies which bind to an epitope on the leukocyte adhesion receptor and suppresses the ability of leukocytes to adhere to each other. These monoclonal antibodies, if desired, can be therapeutically or diagnostically labelled.
REFERENCES:
patent: 4797277 (1989-01-01), Arfors
patent: 5091513 (1992-02-01), Huston et al.
patent: 5543144 (1996-08-01), Chang
patent: WO 8904174 (1988-11-01), None
patent: WO 8806592 (1998-09-01), None
Hildreth et al, J. Immunology 134; 3272-80, 1985.
Faley et al, Clin Exp. Immunol. 88:1-5, 1992.
Vedder et al, J. Clin. Invest. 81: 939-44, 1988.
Harris et al., Tibtech 11: 42-44, 1993.
Pastan et al, Coll 47: 641-648, 1986.
James E. Hildreth and Jennifer a. Hyman, Production and Characterization of Monoclonal Anti-CD-8 Anti-Idiotype Antibodies; Molecular Immunology, 26(12): 1155-1167, 1989.
McMichael Leucocyte Typing III Where Cell Differentiation Antigents, Oxford University Press, 1987, preface.
Ward et al, Therapeutic Immunology vol. 1: 165-171, 1994.
James E. Hildreth and J. Thomas August, The Human Lymphocyte Function-Associated (HLFA) Antigen and a Related macrophage Differentiation . . . ; The Journal of Immunology, 134(5): 3272-3280, 1985.
Corbi et al, Chromosomal Location of the Genes Encoding the Leukocyte Adhesion Receptors LFA-1, Mac-1 and p150,95, J.Exp.Med 167: pp. 1597-1607 (May 1988).
Dongworth et al (European Journal of Immunology vol. 15(9) pp. 888-892), 1985.
Gray Cary Ware & Freidenrich LLP
Haile Lisa A.
Navarro Albert
The Johns Hopkins University School of Medicine
LandOfFree
Monoclonal antibodies against leukocyte adhesion receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against leukocyte adhesion receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against leukocyte adhesion receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2611138